Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation
(Thomson Reuters ONE) -
Summary: Bavarian Nordic increases its share capital by nominally DKK
13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct
placement to Johnson & Johnson Development Corporation ("JJDC") in connection
with the license and supply agreement for the Company's MVA-BN® vector in
respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical
companies of Johnson & Johnson.
KVISTGAARD, Denmark, October 29, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announces the completion of the direct placement of 1,331,984 new shares
of nominal value DKK 10 each (corresponding to approximately 4.85% of the
Company's share capital after completion of the direct placement) in Bavarian
Nordic at a subscription price of DKK 188.4407 per new share to JJDC, raising
gross proceeds to Bavarian Nordic of DKK 250,999,997.35.
The direct placement, which is made in connection with the license and supply
agreement for the Company's MVA-BN® vector in respect of Ebola between Bavarian
Nordic and Crucell Holland B.V., one of the Janssen Pharmaceutical companies of
Johnson & Johnson, was originally announced on 22 October 2014 (Company
Announcements Nos. 22 and 23).
Bavarian Nordic's share capital will amount to DKK 274,448,470 after
registration of the capital increase with the Danish Business Authority.
Bavarian Nordic's new articles of association will be published separately and
will be available at Bavarian Nordic's website, www.bavarian-nordic.com.
It is expected that the new shares will be admitted to trading and official
listing on Nasdaq Copenhagen on 31 October 2014.
Contacts
Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX.
Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.
For more information, visit www.bavarian-nordic.com.
About MVA-BN®
MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and
patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and
adaptable platform suitable for addressing a wide variety of infectious
diseases, including biological threats.
In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU
and Canada) essential to protecting the immune-compromised population, Bavarian
Nordic has conducted more than a dozen preclinical and clinical studies of
recombinant MVA-BN-based vaccines. More than 7,500 individuals, nearly 1,000 of
whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines,
showing the platform displays high immunogenicity and a favorable safety
profile.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201425uk:
http://hugin.info/100065/R/1866653/655750.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1866653]
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2014 - 10:14 Uhr
Sprache: Deutsch
News-ID 347793
Anzahl Zeichen: 5230
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
